Exabis Library
Welcome to the e-CCO Library!
DOP43: The risk of extra-intestinal cancer in Inflammatory Bowel Disease (IBD): A systematic review and meta-analysis of population-based cohort studies
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP43: The risk of extra-intestinal cancer in Inflammatory Bowel Disease (IBD): A systematic review and meta-analysis of population-based cohort studies
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multicentric study from GETECCU
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP44: Melatonin Ameliorates Colitis In DSS-fed Mice Via The SIRT1 Pathway
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP45: Blood-derived neutrophils give rise to differentially activated populations in the mucosa of active Inflammatory Bowel Disease patients
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM